Form 4: Guardant Health Exec Reports Stock Transactions

Guardant Health Co-CEO Helmy Eltoukhy reported transactions involving common stock and restricted stock units on June 30 and July 1, 2026.

Summary

• Helmy Eltoukhy, Co-Chief Executive Officer and Director of Guardant Health, Inc., filed a Form 4 detailing stock transactions.
• On June 30, 2026, 2,817 shares of common stock were acquired (Transaction Code M) with a reported value of $0, and 1,428 shares were disposed of (Transaction Code F) at a price of $150.03.
• On July 1, 2026, additional acquisitions of common stock occurred: 23,997 shares (Transaction Code M) at $0 and 9,715 shares (Transaction Code M) at $0.
• Also on July 1, 2026, 17,086 shares were disposed of (Transaction Code F) at a price of $170.77.
• These transactions resulted in Eltoukhy beneficially owning 2,015,736 shares held by the Helmy A. Eltoukhy Revocable Trust, and a total of 2,038,305, 2,048,020, and 2,030,934 shares following the reported transactions.
• The filing also notes transactions related to Restricted Stock Units (RSUs): 2,817 RSUs were acquired on June 30, 2026, and 23,997 and 9,715 RSUs were acquired on July 1, 2026.
• Explanation of responses clarifies that shares retained by the company were to meet tax withholding obligations and were not in excess of tax liability.
• Details are provided on the vesting schedules for the RSUs, including awards granted on March 17, 2026, March 18, 2024, and March 12, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine insider transactions related to compensation and personal portfolio management rather than a strategic shift or significant event.

Positives

• Acquisition of 2,817 shares of common stock on June 30, 2026, at no cost.
• Acquisition of 23,997 shares of common stock on July 1, 2026, at no cost.
• Acquisition of 9,715 shares of common stock on July 1, 2026, at no cost.
• Acquisition of 2,817 Restricted Stock Units on June 30, 2026.
• Acquisition of 23,997 Restricted Stock Units on July 1, 2026.
• Acquisition of 9,715 Restricted Stock Units on July 1, 2026.

Negatives

• Disposition of 1,428 shares of common stock on June 30, 2026, at a price of $150.03.
• Disposition of 17,086 shares of common stock on July 1, 2026, at a price of $170.77.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings and trading activities of company executives and directors. These transactions can offer insights into management's confidence in the company's future prospects, though they are often driven by personal financial planning and compensation structures.

Stakeholder Impact

• Shareholders: The transactions provide transparency into insider holdings and potential selling pressure, but do not inherently signal a change in company performance.
• Employees: The details on Restricted Stock Unit vesting schedules offer insight into executive compensation plans.
• Management: The filing confirms the beneficial ownership structure of the reporting person and their associated trust.

Key Dates

Keywords

Guardant Health, GH, Form 4, Insider Trading, Stock Transaction, Restricted Stock Units, Beneficial Ownership, Helmy Eltoukhy, CEO, Director